Goodwin London co-chair Paul Lyons thanked the firm’s clients’ continued trust and dedication of all members of the Goodwin community during the pandemic when reflecting on the firm’s financials over the past year. Read the announcement in The Lawyer here.
Related Content
- Big Molecule WatchApril 19, 2024
Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Life Sciences PerspectivesApril 10, 2024
Janssen v. Teva: Not an April Fool’s Day Joke for Life Sciences Companies
- Big Molecule WatchApril 9, 2024
FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU
- Life Sciences PerspectivesApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement
- Press ReleaseApril 10, 2024
Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion
- In the PressApril 9, 2024
Goodwin Picks Up Tech Team, Eyeing AI-Fueled Rebound (Bloomberg Law)
- In the PressApril 9, 2024
Deal Watch: M&A (Law.com)